With cash in the bank and an eye on Europe, Neurocrine buys out a London-based outfit
As rising sales for its lead product give Neurocrine some extra cash to work with, the biotech is jumping on a buyout. Just don’t look for anything huge.
Neurocrine is acquiring London-based Diurnal Group for £48.3 million, or $56.57 million, in cash. On top of its two marketed treatments for chronic endocrine diseases, Neurocrine is hoping to bring in Diurnal’s team of 33 — all of which will beef up its clinical development and commercial capabilities in Europe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
